{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:22:23Z","timestamp":1740126143672,"version":"3.37.3"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,17]]},"DOI":"10.1093\/bjd\/ljae035","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T06:11:38Z","timestamp":1706508698000},"page":"615-616","source":"Crossref","is-referenced-by-count":0,"title":["Improving cancer stem cells killing in malignant melanoma"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3955-1091","authenticated-orcid":false,"given":"Daniele","family":"Bergamaschi","sequence":"first","affiliation":[{"name":"Centre for Cell Biology and Cutaneous Research, Blizard Institute, Faculty of Medicine & Dentistry, Queen Mary University of London , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"2024041719052171900_ljae035-B1","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol"},{"key":"2024041719052171900_ljae035-B2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2024041719052171900_ljae035-B3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/CMR.0000000000000654","article-title":"Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)","volume":"30","author":"Atkinson","year":"2020","journal-title":"Melanoma Res"},{"key":"2024041719052171900_ljae035-B4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/bjd\/ljad502","article-title":"Targeting CD20 expressing malignant melanoma cells augments BRAF inhibitor killing","volume":"190","author":"Mukhtar","year":"2024","journal-title":"Br J Dermatol"},{"key":"2024041719052171900_ljae035-B5","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41467-020-15546-9","article-title":"Pre-clinical modeling of cutaneous melanoma","volume":"11","author":"Rebecca","year":"2020","journal-title":"Nat Commun"},{"key":"2024041719052171900_ljae035-B6","doi-asserted-by":"crossref","first-page":"104614","DOI":"10.1016\/j.ebiom.2023.104614","article-title":"Patient-derived melanoma organoid models facilitate the assessment of immunotherapies","volume":"92","author":"Ou","year":"2023","journal-title":"EBioMedicine"},{"key":"2024041719052171900_ljae035-B7","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1158\/0008-5472.CAN-05-1343","article-title":"A tumorigenic subpopulation with stem cell properties in melanomas","volume":"65","author":"Fang","year":"2005","journal-title":"Cancer Res"},{"key":"2024041719052171900_ljae035-B8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/mt.2012.27","article-title":"Targeting CD20 in melanoma patients at high risk of disease recurrence","volume":"20","author":"Pinc","year":"2012","journal-title":"Mol Ther"},{"key":"2024041719052171900_ljae035-B9","doi-asserted-by":"crossref","first-page":"733961","DOI":"10.3389\/fimmu.2021.733961","article-title":"Case report: \u00adsustained\u00a0remission due to PD-1-inhibition in a metastatic melanoma patient with depleted B cells","volume":"12","author":"Wulfken","year":"2021","journal-title":"Front Immunol"},{"key":"2024041719052171900_ljae035-B10","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00262-018-2145-9","article-title":"Rituximab as a therapeutic option for patients with advanced melanoma","volume":"67","author":"Winkler","year":"2018","journal-title":"Cancer Immunol Immunother"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae035\/56828412\/ljae035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/5\/615\/57262144\/ljae035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/5\/615\/57262144\/ljae035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T02:24:22Z","timestamp":1731119062000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/5\/615\/7590956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":10,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,1,29]]},"published-print":{"date-parts":[[2024,4,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae035","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"type":"print","value":"0007-0963"},{"type":"electronic","value":"1365-2133"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,1,29]]}}}